Core Viewpoint - The company currently does not have certified Nipah virus testing products and will evaluate the situation based on clinical urgency, technical feasibility, and compliance with registration procedures [1]. Group 1 - The company responded to investor inquiries regarding the recent outbreak of the Nipah virus, indicating a lack of existing testing products [1][3]. - The company emphasizes a careful decision-making process regarding product development, considering multiple dimensions such as clinical needs and regulatory compliance [1].

Group 1 - The company has the technical capability to provide testing solutions for Chikungunya virus and Dengue virus [2] - The company has established a third-party medical laboratory in Haikou, Hainan Province, and has obtained a medical institution practice license [2] - Investors are encouraged to refer to the company's regular reports for specific operational details [2]

Core Viewpoint - The company, Capbio (300639.SZ), has announced its capability to provide comprehensive testing solutions for Chikungunya virus and Dengue virus through its medical laboratory [1] Group 1 - The company offers testing capabilities for Chikungunya virus [1] - The company provides testing capabilities for Dengue virus [1] - The solutions are part of the company's overall service offerings in the medical laboratory sector [1]